Is bpth good stock to buy now

**Bio-Path Holdings (BPTH) is not a good stock to buy at this moment**. Here's why:

1. **Poor Recent Performance**: The stock has experienced a significant decline of 1.85% on October 29, 2024, closing at $1.06. This indicates a weak recent performance.

2. **Technical Indicators Show Weakness**: The stock's technical indicators are not favorable. The Relative Strength Index (RSI) is at 49.27, which is close to the oversold threshold but not yet there, suggesting the stock is neither overbought nor oversold. However, the Moving Average Convergence Divergence (MACD) is at 0, which typically suggests a lack of momentum.

3. **Market Sentiment is Bearish**: The stock has a Sell rating from our Quant rating system, and the consensus among analysts is not optimistic. This is reflected in the stock's price-to-earnings (P/E) ratio, which is negative at -0.29, indicating that the company is not profitable as currently reported.

4. **Fund Flow is Negative**: The net fund flow is positive at $16,028.26, but the extra-large and block order flows are zero, which could indicate a lack of significant institutional interest or a market where large orders are not being placed.

5. **Strategic Expansion May Offer Future Prospects**: The company has announced the launch of a new therapeutic program for obesity treatment, which could be a positive long-term development. However, this does not negate the current poor stock indicators.
6. **Risk of Underperformance**: The company's decelerating momentum and negative EPS revisions compared to other Health Care stocks suggest a high risk of underperformance. This is a significant concern for investors looking for growth or stability.

In conclusion, while the announcement of a new therapeutic program may offer potential for the future, the current stock indicators and market sentiment suggest that BPTH is not a good investment at this time. Investors should exercise caution and consider the potential risks before making a decision to buy.